Director, Global Translational Lead Takeda Pharmaceutical Company Limited Cambridge, Massachusetts, United States
Cell therapies have become an attractive and promising modality in treating both hematological and solid malignancies. While CAR-T cells paved the way, allogeneic platforms such involving NK cells and γδ T cells are increasingly becoming attractive platforms for cell therapies. This session will cover 1) The basic biology of γδ T cells and the characteristics that make it an attractive platform for allogeneic cell therapy in cancer 2) A brief comparison of γδ T cells with NK and autologous T cells 3) Analytical activities that are needed to meet the regulatory requirements and maximize clinical understanding of the product/platform with special emphasis on cellular kinetics, immunogenicity, and other disease characteristics
Learning Objectives:
Upon completion, the participants will be able to discuss the biological features of γδ T cells, its various subsets and potential sources
Upon completion, the participants will be able to understand the critical components of a well-designed translational plan for cell therapy trials
Upon completion, the paticipants will be able to provide an overview of available technologies to monitor exposure, product characterization (phenotypic and functional) and biomarkers of clinical response
